HROG17 T1 M1 Cells

HROG17 T1 M1 is a primary human glioblastoma multiforme (GBM) cell line established from a tumor specimen resected from an adult patient diagnosed with WHO grade IV glioblastoma. The designation “T1” indicates that the sample was obtained at the first surgical time point, while “M1” denotes the corresponding in vitro model derived from this tumor. The cell line was generated within the HROG (Hansestadt Rostock Glioma) platform, which focuses on establishing ultra-low passage glioma cultures that preserve patient-specific molecular and phenotypic characteristics.

HROG17 T1 M1 grows adherently under standard culture conditions and exhibits a fibroblast-like morphology typical of primary GBM cultures. Immunophenotypic characterization of HROG-derived lines demonstrates expression of glial and neural lineage-associated markers such as glial fibrillary acidic protein (GFAP), nestin, and vimentin, consistent with high-grade astrocytic tumor origin. Molecular profiling within the HROG collection includes evaluation of clinically relevant parameters such as MGMT promoter methylation, EGFR amplification status, and mutational analysis of key genes including TP53, IDH1/2, KRAS, and BRAF, supporting retention of tumor-specific genomic alterations in culture.

HROG17 T1 M1 has been used to assess sensitivity to standard-of-care agents for glioblastoma, including alkylating chemotherapeutics and additional targeted compounds. Comparative analyses across HROG models indicate that low-passage cultures maintain stable morphology, growth kinetics, and drug response profiles over early passages. As a patient-derived, low-passage glioblastoma model, HROG17 T1 M1 provides a clinically relevant in vitro platform for studying tumor biology, therapeutic response, and intertumoral heterogeneity in high-grade glioma.